Author

T. G. Kutateladze

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Acharya· 1 shared A. Kallam· 1 shared A. L. Smith· 1 shared A. P. Eiken· 1 shared C. R. D'Angelo· 1 shared D. El-Gamal· 1 shared D. L. Durden· 1 shared D. Y. Moore· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. Acharya

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivMay 11, 2022

A novel triple-action inhibitor targeting B-cell receptor signaling and BRD4 demonstrates preclinical activity in chronic lymphocytic leukemia

A. L. Smith, A. P. Eiken, D. Y. Moore…·D. El-Gamal

This study shows that SRX3305, a triple-action inhibitor targeting BTK, PI3K, and BRD4, reduces CLL cell proliferation, promotes apoptosis, and blocks migration in preclinical models.

DOI 10.3390/ijms23126712

humanexperimental assay

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivPreprintMar 2, 2021

Blockade of SARS-CoV-2 infection in-vitro by highly potent PI3K-α/mTOR/BRD4 inhibitor

A. Acharya, K. Pandey, M. Thurman…·S. N. Byrareddy

The paper demonstrates that SF2523, a PI3K-α/mTOR/BRD4 inhibitor, effectively blocks SARS-CoV-2 replication in vitro with an IC50 of 1.5 μM and shows synergy with remdesivir.

DOI 10.1101/2021.03.02.433604

humanexperimental assay

𝕏 PostBluesky